Cartesian Therapeutics, Inc.
RNAC
$6.42
-$0.23-3.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -92.81% | -97.72% | -98.10% | 31.91% | 49.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.81% | -97.72% | -98.10% | 31.91% | 49.64% |
| Cost of Revenue | 29.24% | 9.63% | 1.55% | -11.55% | -31.61% |
| Gross Profit | -821.85% | -2,699.79% | -2,033.67% | 48.26% | 84.89% |
| SG&A Expenses | 6.58% | -21.71% | -24.78% | -23.52% | -15.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.25% | -4.08% | -9.78% | -16.35% | -25.87% |
| Operating Income | -144.12% | -106.25% | -122.31% | 34.58% | 52.26% |
| Income Before Tax | -80.84% | 81.92% | 85.53% | 86.12% | 67.69% |
| Income Tax Expenses | -3,303.14% | 101.51% | 101.51% | 101.51% | 101.51% |
| Earnings from Continuing Operations | -68.30% | 80.40% | 84.21% | 84.97% | 64.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.30% | 80.40% | 84.21% | 84.97% | 64.76% |
| EBIT | -144.12% | -106.25% | -122.31% | 34.58% | 52.26% |
| EBITDA | -143.68% | -103.97% | -120.47% | 36.93% | 53.28% |
| EPS Basic | 53.03% | 96.36% | 96.89% | 97.17% | 78.16% |
| Normalized Basic EPS | 16.35% | 91.65% | 92.83% | 97.07% | 91.12% |
| EPS Diluted | 53.06% | 96.34% | 96.87% | 97.11% | 78.09% |
| Normalized Diluted EPS | 17.68% | 91.70% | 92.87% | 96.97% | 91.02% |
| Average Basic Shares Outstanding | 50.50% | 111.25% | 203.07% | 326.63% | 233.80% |
| Average Diluted Shares Outstanding | 48.87% | 107.67% | 194.85% | 331.72% | 238.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |